Compass Therapeutics Company Insiders
| CMPX Stock | USD 2.51 0.06 2.33% |
Slightly above 66 percent of all Compass Therapeutics' insiders are acquiring. The analysis of the overall insider sentiment regarding Compass Therapeutics suggests that a large number of insiders are confidant. Compass Therapeutics employs about 35 people. The company is managed by 12 executives with a total tenure of roughly 82 years, averaging almost 6.0 years of service per executive, having 2.92 employees per reported executive.
Insider Sentiment 66
Mostly Buying
Selling | Buying |
Latest Trades
| 2025-05-27 | Thomas J Schuetz | Acquired 10000 @ 2.11 | View | ||
| 2025-04-09 | Carl L Gordon | Disposed 3571428 @ 1.59 | View | ||
| 2025-04-07 | Jonathan Anderman | Acquired 20000 @ 1.54 | View |
Monitoring Compass Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Compass Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Compass Therapeutics' future performance. Based on our forecasts, it is anticipated that Compass will maintain a workforce of slightly above 40 employees by July 2025.Compass Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2641) % which means that it has lost $0.2641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4131) %, meaning that it created substantial loss on money invested by shareholders. Compass Therapeutics' management efficiency ratios could be used to measure how well Compass Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.32 in 2025. Net Tangible Assets is likely to rise to about 219.3 M in 2025, whereas Total Assets are likely to drop slightly above 125.3 M in 2025.Common Stock Shares Outstanding is likely to drop to about 89.2 M in 2025. Net Loss is likely to drop to about (37.1 M) in 2025
Compass Therapeutics Workforce Comparison
Compass Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,602. Compass Therapeutics claims roughly 35.0 in number of employees contributing just under 2% to equities under Health Care industry.
Compass Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Compass Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Compass Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Compass Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-06-01 | 1.5 | 3 | 2 | 50,000 | 7,142,856 |
| 2025-03-01 | 5.0 | 10 | 2 | 2,470,000 | 99,741 |
| 2024-09-01 | 0.1667 | 1 | 6 | 300,000 | 425,000 |
| 2024-03-01 | 5.0 | 10 | 2 | 5,021,250 | 93,980 |
| 2022-12-01 | 0.6667 | 2 | 3 | 804,000 | 24,500 |
| 2022-06-01 | 13.5 | 27 | 2 | 1,111,303 | 0.00 |
| 2021-06-01 | 3.0 | 3 | 1 | 2,101,549 | 0.00 |
| 2020-06-01 | 1.2 | 6 | 5 | 3,610,879 | 0.00 |
| 2006-03-01 | 0.2 | 2 | 10 | 60,000 | 663,572 |
| 2005-12-01 | 1.0 | 1 | 1 | 19,000 | 19,000 |
Compass Therapeutics Notable Stakeholders
A Compass Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Compass Therapeutics often face trade-offs trying to please all of them. Compass Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Compass Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan JD | General President | Profile | |
| James Kranz | VP Controls | Profile | |
| Susan Kalled | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Barry JD | Chief Officer | Profile | |
| Neil CPA | Senior Officer | Profile | |
| Peter Moesta | Interim CMC | Profile | |
| Anna Gifford | Communications Manager | Profile | |
| Karin BA | Senior Operations | Profile | |
| Vered MBA | Pres COO | Profile | |
| MBA JD | Chief Officer | Profile | |
| Minori MD | Senior Development | Profile |
About Compass Therapeutics Management Performance
The success or failure of an entity such as Compass Therapeutics often depends on how effective the management is. Compass Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Compass management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Compass management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.33) | (0.35) |
Please note, the imprecision that can be found in Compass Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Compass Therapeutics. Check Compass Therapeutics' Beneish M Score to see the likelihood of Compass Therapeutics' management manipulating its earnings.
Compass Therapeutics Workforce Analysis
Traditionally, organizations such as Compass Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Compass Therapeutics within its industry.Compass Therapeutics Manpower Efficiency
Return on Compass Therapeutics Manpower
| Revenue Per Employee | 24.3K | |
| Revenue Per Executive | 70.8K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 4.1M | |
| Working Capital Per Employee | 3.5M | |
| Working Capital Per Executive | 10.3M |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.